Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Cost of RevenueDepreciation ExpenseEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsReceivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Akebia Therapeutics (AKBA) Cost of Revenue (2018 - 2026)

Akebia Therapeutics has reported Cost of Revenue over the past 7 years, most recently at $12.5 million for Q4 2025.

  • Quarterly Cost of Revenue rose 179.96% to $12.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $39.5 million through Dec 2025, up 332.98% year-over-year, with the annual reading at $39.5 million for FY2025, 45.43% up from the prior year.
  • Cost of Revenue was $12.5 million for Q4 2025 at Akebia Therapeutics, up from $9.4 million in the prior quarter.
  • Over five years, Cost of Revenue peaked at $52.5 million in Q2 2021 and troughed at -$17.4 million in Q4 2023.
  • The 5-year median for Cost of Revenue is $11.4 million (2021), against an average of $13.4 million.
  • Year-over-year, Cost of Revenue crashed 173.62% in 2023 and then skyrocketed 179.96% in 2025.
  • A 5-year view of Cost of Revenue shows it stood at $11.6 million in 2021, then skyrocketed by 103.74% to $23.6 million in 2022, then crashed by 173.62% to -$17.4 million in 2023, then increased by 9.78% to -$15.7 million in 2024, then surged by 179.96% to $12.5 million in 2025.
  • Per Business Quant, the three most recent readings for AKBA's Cost of Revenue are $12.5 million (Q4 2025), $9.4 million (Q3 2025), and $9.9 million (Q2 2025).